Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Demetri, G; Reichardt, P; Kang, Y; Blay, J; Rutkowski, P; Gelderblom, H; Hohenberger, P; Leahy, Michael G; von Mehren, M; Joensuu, H; Badalamenti, G; Blackstein, M; Le Cesne, A; Schöffski, P; Maki, R; Bauer, S; Nguyen, B; Xu, J; Nishida, T; Chung, J; Kappeler, C; Kuss, I; Laurent, D; Casali, P

Affiliation

Ludwig Center at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

Issue Date

2013-01-26

Metadata

Show full item record

Abstract

Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib.

Citation

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. 2013, 381 (9863):295-302 Lancet

Journal

Lancet

URI

http://hdl.handle.net/10541/273028

DOI

10.1016/S0140-6736(12)61857-1

PubMed ID

23177515

Type

Article

Language

ISSN

1474-547X

Collections

All Christie Publications